Stacy W. Gray, M.D., A.M.

- Clinical Cancer Genomics
- Translational Genomics
- Understanding the Factors that Drive the Use of Novel and Established Cancer Genomic Tests and Therapies
- Identifying Gaps in Lung Cancer Prevention, Research and Care
- Designing Interventions to Improve the Delivery of Cancer Medicine
- Director, Clinical and Scientific Strategy, and Vice President, System Strategy
- Professor, Medical Oncology & Therapeutics Research, Population Sciences
Stacy W. Gray, M.D., A.M., is Director, Clinical and Scientific Strategy, and Vice President, System Strategy, and a professor in the Division of Clinical Cancer Genomics within the Department of Medical Oncology & Therapeutics Research with a secondary appointment in the Department of Population Sciences.
Dr. Gray earned her undergraduate degree from Brown University. She received both her master’s degree in public policy and her medical doctorate from University of Chicago. She completed her internal medicine residency and hematology/oncology fellowship at University of Chicago Hospitals.
During her clinical training, she was awarded an Irving B. Harris Fellowship. Subsequently, she completed a research fellowship at the National Cancer Institute-funded Center of Excellence in Cancer Communication Research at University of Pennsylvania’s Annenberg School for Communication.
She continued her research training through a second postdoctoral fellowship at Massachusetts General Hospital, simultaneously joining Dana-Farber as a medical oncologist and cancer outcomes researcher in the Division of Population Sciences and the Lowe Center for Thoracic Oncology.
Dr. Gray's research is in translational genomics. She is working to understand the factors that drive the use of novel and established cancer genomic tests and therapies, identify gaps in lung cancer prevention, research and care, and design interventions to improve the delivery of precision cancer medicine.
Dr. Gray served on the ASCO Cancer Research Committee, holds multiple leadership roles in an National Institutes of Health research consortium, and has presented her research both nationally and internationally. She has numerous peer-reviewed publications in such journals as Journal of Clinical Oncology, Journal of the National Cancer Institute, Journal of Oncology Practice, and Genetics in Medicine.
Dr. Gray also has a strong track record of research funding and has been supported by National Human Genome Research Institute, Agency for Healthcare Research and Quality, American Cancer Society, American Society of Clinical Oncology and Robert Wood Johnson Foundation.
Location
Duarte Cancer Center
Duarte, CA 91010
Orange County Lennar Foundation Cancer Center
Irvine, CA 92618
Education & Experience
Board Certifications
- 2006–present, Diplomate, American Board of Internal Medicine, Subspecialty in Medical Oncology
- 2002, Diplomate, American Board of Internal Medicine
Degrees
- 2005, A.M., Public Policy, University of Chicago, Chicago, IL
- 1999, M.D., Medicine, University of Chicago, Chicago, IL
- 1994, B.A., History, Brown University, Providence, RI
Fellowship
- 2008–2010, Research Fellow, Program in Cancer Outcomes Research Training, Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA
- 2005–2007, Research Fellow, Cancer Communication Research, Annenberg School for Communication at University of Pennsylvania, Philadelphia, PA
- 2002–2005, Clinical Fellow, Hematology/Oncology, University of Chicago, Chicago, IL
Residency
- 1999–2002, Resident, Internal Medicine, University of Chicago
Professional Experience
- 2025 to present, Director, Clinical and Scientific Strategy, and Vice President, System Strategy, City of Hope, Duarte, CA
- 2023 to present, Professor, Division of Clinical Cancer Genomics, Department of Medical Oncology & Therapeutics Research, and Department of Population Sciences, City of Hope, Duarte, CA
- 2021 to 2025, Division Chief, Clinical Cancer Genomics, Department of Medical Oncology & Therapeutics Research, and Department of Population Sciences, City of Hope, Duarte, CA
- 2016–2022, Associate Professor, Division of Clinical Cancer Genomics, Department of Medical Oncology & Therapeutics Research, and Department of Population Sciences, City of Hope, Duarte, CA
- 2016–present, Staff Physician, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
- 2012–2016, Assistant Professor, Medicine, Harvard Medical School, Boston, MA
- 2008–2016, Active Staff, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
- 2008–2016, Associate Physician, Medicine/Oncology, Brigham and Women’s Hospital, Boston, MA
- 2008–2012, Instructor, Medicine, Harvard Medical School
- 2007–2008, Research Associate, Annenberg School for Communication, University of Pennsylvania
- 2007–2008, Staff Physician, Medicine/Hematology and Oncology, The Hospital of the University of Pennsylvania
- 2007–2008, Instructor, Medicine, University of Pennsylvania
Awards & Memberships
Awards
- 2022, LA Business Journal 2022 Top Doctors List
- 2022, Fellowship — Carol Emmott Fellow — National Fellowship for Women Leaders in Health
- 2019, Transformational Leadership Development Program — Leadership Training, City of Hope
- 2019, NIH, Genomic Innovator Award
- 2015, Harvard Catalyst Training Institute — Leadership Training, Hard Clinical and Translational Science Center
- 2014, GRASP Program — Research, Harvard Clinical and Translational Science Center
- 2009, “Rising Star” Award — Research, Dana-Farber Cancer Institute
- 2008, Loan Repayment Program — Research-based Loan Forgiveness, National Institutes of Health
- 2006, Young Investigator Award — Research, American Society for Clinical Oncology
- 2004, Merit Award — Research, American Society for Clinical Oncology
- 2003, Irving B. Harris Fellowship — Academic Achievement, University of Chicago, Harris School of Public Policy
- 2003, Fellow Award — Clinical and Teaching, University of Chicago, Internal Medicine Residency
- 2002, Resident Award — Clinical and Teaching, University of Chicago, Internal Medicine Residency
- 2001, Hilger Perry Jenkins Award: Excellence in Academic and Patient-Oriented Service — Academic, Clinical and Teaching, University of Pritzker School of Medicine
Memberships
- 2022–present, Member, Annual Meeting Scientific Committee: Cancer Care Delivery and Regulatory Policy
- 2022–present, Co-Chair, Guideline Committee: cfDNA Testing in Solid Tumors and Lymphoma, ASCO
- 2022–present, Member, American Association for Cancer Research
- 2019–present, Member, American College of Genetics and Genomics
- 2019–2022, Member, Guideline Committee: Somatic Genomic Panel Testing in Metastatic Disease, ASCO
- 2019–2020, Member, World Conference on Lung Cancer Pathology, Molecular Pathology and Diagnostic Biomarker Committee, IASLC
- 2018–present, Member, International Association for the Study of Lung Cancer
- 2018, Member, Lung Cancer Research Foundation
- 2017–2021, Member, TAPUR Molecular Tumor Board, ASCO
- 2016–2019, Member, Cancer Research Committee, ASCO
- 2015–2020, Member, TAPUR Physician Perceptions and Use of Molecular Testing Study Advisor Group, ASCO
- 2012–present, Member, American Society of Human Genetics
- 2011, Member, International Communication Association
- 2011, Member, Society for Medical Decision Making
- 2006–present, Member, American Society for Preventive Oncology
- 2002–present, Member, American Society of Clinical Oncology
Publications
- Gray SW, Hlubocky F, Ratain M, and Daugherty CK. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007 August 10; 25 (23): 3488-94. PMID: 17687154
- Gray SW, Armstrong K, DeMichele A, Schwartz JS, Hornik R. Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications. Cancer. 2009 Apr 1;115 (7):1424-34. PMID: 19235785
- Gray SW, O’Grady C, Karp L, Smith D, Schwartz JS, Hornik R, Armstrong K. Risk information exposure and direct-to-consumer genetic testing for BRCA mutations among women with a personal or family history of breast or ovarian cancer. Cancer Epidemiol, Biomarkers and Prev. 2009 Apr; 18(4): 1303-11. PMID: 19318436
- Gray SW, Landrum MB, Lamont EB, McNeil BJ, Jaklitsch MT, Keating NL. Improved outcomes associated with higher surgery rates for older patients with early-stage non-small cell lung cancer. Cancer. 2012. Mar 1;118 (5):1404-1411. PMID: 21800285
- Gray SW, Hornik R, Schwartz JS, Armstrong K. The impact of risk information exposure of women’s beliefs about direct-to-consumer genetic testing for BRCA mutations. Clin Genet. 2012 Jan;81(1):29-37. PMID: 21992449
- Gray SW, Hicks-Courant K, Lathan C, Garraway L, Park ER, Weeks JC. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J Oncol Pract 2012; Nov 1, 2012 (329-335) Epub 2012 August 7. PMID: 23598841
- Tarczy-Hornoch P, Amendola L, Aronson SJ, Garraway L, Gray S, Grundmeier RW, Hindorff LA, Jarvik G, Karavite D, Lebo M, Plon SE, Van Allen E, Weck KE, White PS, Yang Y., A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genet Med. 2013 Oct;15(10):824-32, Epub 2013 Sep 26. PMID: 24071794
- Berg JS, Amendola LM, Eng C, Allen EV, Gray SW, Wagle N, Rehm HL, Dechene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, Evans JP, Jarvik GP. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med. 2013 Nov;15(11):860-7, Epub 2013 Oct. PMID: 24195999
- Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC, Physicians’ attitudes about multiplex tumor genomic testing, J Clin Oncol. 2014 May 1;32(13):1317-23. Epub 2014 Mar 24. PMID: 24663044
- Gray SW, Martins Y, Feuerman LZ, Bernhardt BA, Biesecker BB, Christensen KD, Joffe S, Rini C, Veenstra D, McGuire AL, Social and Behavioral Research in Genomic Sequencing- Approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group, Genet Med. 2014 Oct;16(10):727-35. Epub 2014 Mar 13. PMID: 24625446